Literature DB >> 19442052

Overcoming drug resistance by enhancing apoptosis of tumor cells.

Pepita Giménez-Bonafé1, Avelina Tortosa, Ricardo Pérez-Tomás.   

Abstract

Drug resistance remains a major clinical challenge for cancer treatment. One mechanism by which tumor cells develop resistance to cytotoxic agents and radiation is related to resistance to apoptosis. Apoptosis is a well-organised process of cell death pre-programmed inside the cell. Apoptosis can be initiated either by activation of death receptors on the cell surface membranes (extrinsic pathway) or through a series of cellular events primarily processed at mitochondria (intrinsic pathway). Apoptosis has been shown to be important for tumorigenesis and cancer treatment. Defects in apoptosis can result in the expansion of a population of neoplastic cells. However, because the death of tumor cells induced by chemotherapy and radiotherapy is largely mediated by activation of apoptosis, inhibition of apoptosis will make tumor cells resistant to anti-tumor treatment. Herein, we will review the molecular changes that have the potential to cause apoptotic dysregulation, including activation of antiapoptotic factors (Bcl-2, BCLX(L), Bfl1/A1 etc.), inactivation of pro-apoptotic effectors (p53, p53 pathway), and /or reinforcement of survival signals (Survivin, FLIP, NF-kappaB etc). Furthermore, we will discuss therapeutic intervention and/or strategies that can lower the threshold for apoptosis of tumor cells that could became useful approaches to treat cancer with special emphasis placed on the important priority to develop new cancer therapeutics toward tumor stem cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19442052     DOI: 10.2174/156800909788166600

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  60 in total

1.  Effect of apoptotic and proliferative indices, P-glycoprotein and survivin expression on prognosis in laryngeal squamous cell carcinoma.

Authors:  Da-Wei Li; Shang Gao; Bin Shen; Pin Dong
Journal:  Med Oncol       Date:  2010-09-23       Impact factor: 3.064

2.  Association of the genetic diversity of killer cell immunoglobulin-like receptor genes and HLA-C ligand in Saudi women with breast cancer.

Authors:  Suliman Y Alomar; Afrah Alkhuriji; Paul Trayhyrn; Abdulkarim Alhetheel; Abdullah Al-Jurayyan; Lamjed Mansour
Journal:  Immunogenetics       Date:  2016-09-15       Impact factor: 2.846

3.  Targeting cannabinoid receptor-2 pathway by phenylacetylamide suppresses the proliferation of human myeloma cells through mitotic dysregulation and cytoskeleton disruption.

Authors:  Rentian Feng; Qin Tong; Zhaojun Xie; Haizi Cheng; Lirong Wang; Suzanne Lentzsch; G David Roodman; Xiang-Qun Xie
Journal:  Mol Carcinog       Date:  2015-01-16       Impact factor: 4.784

Review 4.  Targeting aldose reductase for the treatment of cancer.

Authors:  Ravinder Tammali; Satish K Srivastava; Kota V Ramana
Journal:  Curr Cancer Drug Targets       Date:  2011-06       Impact factor: 3.428

Review 5.  Apoptotic cell signaling in cancer progression and therapy.

Authors:  Jessica Plati; Octavian Bucur; Roya Khosravi-Far
Journal:  Integr Biol (Camb)       Date:  2011-02-22       Impact factor: 2.192

6.  Acquisition of mitochondrial dysregulation and resistance to mitochondrial-mediated apoptosis after genotoxic insult in normal human fibroblasts: a possible model for early stage carcinogenesis.

Authors:  Kristen P Nickens; Ying Han; Harini Shandilya; Ashley Larrimore; Gary F Gerard; Eric Kaldjian; Steven R Patierno; Susan Ceryak
Journal:  Biochim Biophys Acta       Date:  2011-10-25

7.  Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells.

Authors:  Taru Muranen; Laura M Selfors; Devin T Worster; Marcin P Iwanicki; Loling Song; Fabiana C Morales; Sizhen Gao; Gordon B Mills; Joan S Brugge
Journal:  Cancer Cell       Date:  2012-02-14       Impact factor: 31.743

8.  The crosstalk between autophagy and ferroptosis: what can we learn to target drug resistance in cancer?

Authors:  Yulu Zhou; Yong Shen; Cong Chen; Xinbing Sui; Jingjing Yang; Linbo Wang; Jichun Zhou
Journal:  Cancer Biol Med       Date:  2019-11       Impact factor: 4.248

9.  Adenylate Kinase 4 Modulates the Resistance of Breast Cancer Cells to Tamoxifen through an m6A-Based Epitranscriptomic Mechanism.

Authors:  Xiaochuan Liu; Gwendolyn Gonzalez; Xiaoxia Dai; Weili Miao; Jun Yuan; Ming Huang; David Bade; Lin Li; Yuxiang Sun; Yinsheng Wang
Journal:  Mol Ther       Date:  2020-09-05       Impact factor: 11.454

10.  Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy.

Authors:  J Rafael Sierra; Virna Cepero; Silvia Giordano
Journal:  Mol Cancer       Date:  2010-04-12       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.